Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Market watchers are anticipating strong results driven by the robust sales of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential challenges from regul